Wednesday, 26 August 2026European Markets

ATOS Stock Was 9.74% Up On Wednesday

Loading stream...

(vianews) - the market ended the session with atos (ato.pa) rising 9.74% to €3.99 on wednesday, following the last session's downward trend. cac 40 jumped 0.91% to €7,455.64, following the last session's downward trend on what was a somewhat up trend trading session today.

about atos

atos se provides digital transformation solutions and services worldwide. it offers advanced computing solutions; analytics, artificial intelligence, and automation solutions; cloud solutions; customer journey analytics and digital customer experience; decarbonization solutions; digital consulting; digital workplace solutions; edge computing and internet of things solutions; and modern applications and platforms. the company also provides advance detection and response, data protection and governance, digital workplace security, iot and ot security, trusted digital identities, and cybersecurity solutions; and infrastructure and foundation services. it serves financial services and insurance, healthcare and life sciences, manufacturing, public sector and defense, resources and services, telecom, media, and entertainment industries. the company was incorporated in 1982 and is headquartered in bezons, france.

earnings per share

as for profitability, atos has a trailing twelve months eps of €-10.01.

more news about atos (ato.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com